UK Dividends Calendar - Week Ahead
UK Dividends Calendar | ||||||||||||
13 May 2014 13:11 UK MIDDAY BRIEFING: AstraZeneca Continues To Reject PfizerLONDON (Alliance News) - AstraZeneca Tuesday again rejected Pfizer's "opportunistic" GBP63 million takeover approach, as UK politicians grilled executives of both companies about the potential deal and what it will mean for the UK's pharmaceutical industry. 13 May 2014 10:21 TOP NEWS: AstraZeneca Notes Positive Drug Test Amid Pfizer HearingLONDON (Alliance News) - The following is a summary of top news stories Tuesday. 13 May 2014 08:55 UPDATE 1-Chinese police to brief media on GlaxoSmithKline on Wednesday amid probe(Adds GSK declines to comment) BEIJING, May 13 (Reuters) - Chinese police will brief the media on Wednesday about British drug maker GlaxoSmithKline PLC , which has been under investigation for allegedly funneling up to 3 billion yuan to travel agencies to facilitate bribes to doctors and o Read more13 May 2014 08:27 Chinese police to brief media on GlaxoSmithKline on Wednesday amid probeBEIJING, May 13 (Reuters) - China's Ministry of Public Security will brief the media on Wednesday about UK drug maker GlaxoSmithKline PLC, which has been under investigation for allegedly funneling up to 3 billion yuan to travel agencies to facilitate bribes to doctors and officials. An off Read more13 May 2014 07:30 GSK study of coronary heart disease treatment fails to meet objectivesGlaxoSmithKline said its phase III study of darapladib failed to meet the primary endpoint in treating patients with acute coronary syndrome. The study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor, did not achieve a reduction of major coronary pro Read more13 May 2014 07:29 UK MORNING BRIEFING: Taylor Wimpey Leads Strong FTSE 250LONDON (Alliance News) - Mid-cap stocks are leading London equities higher at the open Tuesday, following a strong lead in from the US and Asia, particularly Tokyo. 13 May 2014 06:56 GlaxoSmithKline Heart Disease Treatment Fails Late Stage TrialLONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday its Phase III study for drug darapladib in the treatment of acute coronary syndrome failed to meet its primary endpoint of reducing major coronary events compared to a placebo when added to standard care. The company said that the ov Read more13 May 2014 06:40 GSK says heart drug darapladib fails in second late-stage trialLONDON, May 13 (Reuters) - GlaxoSmithKline said its drug darapladib had not reduced heart attacks or other major events in patients with acute coronary syndrome, marking another disappointment for the innovative heart medicine. Darapladib had already failed in a late-stage trial for patient Read more13 May 2014 05:11 UK Dividends Calendar - Week Ahead
|